ResearcherAsan Medical CenterActive in the last 2 years
Hyehyun Jeong
Matched on ORCID iD 0000-0001-7277-6463; OpenAlex author ID A5004673227. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: none · 2026: 2 papers
Papers 6
- Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… First author DOI 10.1245/s10434-026-19762-3↗
- Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX. Co-author DOI 10.3389/fonc.2026.1762299↗
- Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
- Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
- Acute pancreatitis as an early sign of pancreatic cancer; a retrospective, matched cohort study. Co-author DOI 10.1080/00365521.2024.2414804↗
- Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcin… First author DOI 10.1177/1758835920923424↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Changhoon Yoo · 6 shared papers, 2020–2026 · strength 1.22
- Paper Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated w… DOI 10.3389/fonc.2026.1762299↗
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Acute pancreatitis as an early sign of pancreatic cancer; a retrospective, matched cohort study. DOI 10.1080/00365521.2024.2414804↗
- Dongwook Oh · 4 shared papers, 2024–2026 · strength 0.82
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Acute pancreatitis as an early sign of pancreatic cancer; a retrospective, matched cohort study. DOI 10.1080/00365521.2024.2414804↗
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Kyu‐pyo Kim · 4 shared papers, 2020–2026 · strength 0.70
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Baek‐Yeol Ryoo · 4 shared papers, 2020–2026 · strength 0.70
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Tae Jun Song · 3 shared papers, 2024–2026 · strength 0.60
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Inkeun Park · 3 shared papers, 2024–2026 · strength 0.60
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Hyunseok Yoon · 2 shared papers, 2024–2026 · strength 0.45
- Paper Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated w… DOI 10.3389/fonc.2026.1762299↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Ki Byung Song · 2 shared papers, 2024–2026 · strength 0.41
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Jin‐hong Park · 2 shared papers, 2024–2026 · strength 0.41
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Dae Wook Hwang · 2 shared papers, 2024–2026 · strength 0.41
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Song Cheol Kim · 2 shared papers, 2024–2026 · strength 0.41
- Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Dong Wan Seo · 2 shared papers, 2024 · strength 0.39
- Do Hyun Park · 2 shared papers, 2024 · strength 0.35
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Sun Young Kim · 1 shared paper, 2026 · strength 0.29
- Jong Hyuk Lee · 1 shared paper, 2026 · strength 0.29
- Seung Soo Lee · 1 shared paper, 2026 · strength 0.25
- Woohyung Lee · 1 shared paper, 2026 · strength 0.25
- Sung-Hyun Cho · 1 shared paper, 2024 · strength 0.23
- Gunn Huh · 1 shared paper, 2024 · strength 0.23
- Yoonchan Lee · 1 shared paper, 2024 · strength 0.23
- Zev A. Wainberg · 1 shared paper, 2024 · strength 0.18
- Choong‐kun Lee · 1 shared paper, 2024 · strength 0.18
- Hye Jin Choi · 1 shared paper, 2024 · strength 0.18
- Dae Young Zang · 1 shared paper, 2024 · strength 0.18
- Sung‐Hoon Moon · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.